Table 2. Circulating miRNAs in human cardiometabolic disease.

miRNA	Finding(s)	Intervention/phenotype	Model	Target/pathway	Author
miR-221, -130b, -142-3p	↓, ↑, ↑ Plasma	Obesity	Human (children)	—	Prats-Puig et al.54
miR-17-5p	↓ Plasma	Obesity	Human	—	Heneghan et al.39 Hulsmans et al.40
miR-17-5p	↓ Plasma	Coronary artery disease	Human	—	Fichtlscherer et al.38
miR-326, Let-7a, f	↑, ↓ Plasma exosomes	Treatment naive diabetic	Human	—	Santovito et al.62
Let-7b, miR-130a,	↑, ↓ Serum	Lower glycemic index diet	Human	—	McCann et al.61
miR-221, -130b, -423-5p	↓ Plasma	Obesity	Human	—	Ortega et al.53, 69
miR-221, let-7g	↑ Plasma	Metabolic syndrome, females	Human (♀)	—	Wang et al.74
miR-222, -142-3p	↑ Plasma	Obesity	Human	—	Ortega et al.53, 69
miR-222	↑ Plasma HDL	Familial hyperchosterolemia vs normo-	Human	—	Vickers et al.70
miR-29b, -223, -126	↓ Plasma	T2DM vs matched controls	Human	—	Zampetaki et al.81
miR-15b	↑ Plasma	Obesity/T2DM	Human	—	Pescador et al.108
miR-138, -376a, -503	↓ Plasma	Obesity/T2DM	Human	—	Pescador et al.108
miR-34a, -375	↑ Plasma	T2DM vs IGT and NGT	Human	—	Kong et al.92
miR-122	↓ Plasma	Severe NASH	Human	—	Miyaaki et al.141
miR-375, -802	↑ Serum,	T2DM vs NGT	Human	—	Higuchi et al.99

Abbreviations: HDL, high-density lipoprotein; IGT, impaired glucose tolerance; miRNA, microRNA; NASH, nonalcoholic steatohepatitis; NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus.